Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 376

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 376
---
 If such agreement is ultimately not renewed, the Company expects to enter into an agreement on commercially reasonable terms with another medical geneticist. Reproductive Genetics: Non-Invasive Prenatal Testing (“NIPT”) We have developed a proprietary non -invasiveprenatal screening test which incorporates a proprietary developed bioinformatics pipeline to analyze fetal DNA from maternal blood samples. The test, which can be administered from nine weeks of pregnancy through birth, screens for common genetic alterations including Down, Edwards, and Patau syndromes, sex chromosome abnormalities, specific aneuploidies, and pathogenic microdeletions/microduplications that could result in a range of genetic disorders. Our NIPT also determines the sex of the fetus and is recommended for all pregnant women, regardless of age and/or risk. Oncology: Hereditary Cancer Test This genetic test is designed to detect inherited mutations linked to an increased risk of hereditary cancers, including breast, ovarian, pancreatic, gastric, uterine, prostate, and renal cancers. Utilizing a blood sample, the test evaluates 113 genes for germline mutations, somatic point mutations (“SNV”), indels, and copy number variants (“CNV”), providing insights that are able to confirm clinical diagnoses, forecast disease progression, guide early symptom detection, inform family planning, genetic counseling, and facilitate clinical trial enrollment. This test is intended for patients with personal or familial indications of hereditary cancer. However, it is not designed for somatic mutation detection in tumors. Oncology: Somatic Profiling (Mutation) Cancer Test The genetic test focuses on multi -biomarkergenes related to the homologous recombination repair pathway, aiding in the identification of prostate cancer patients who could benefit from targeted therapies. It analyzes tumor tissue and/or peripheral blood samples to detect germline mutations, assisting in risk assessment for patients and providing disease mechanism insights for optimal treatment decisions. This service is intended for cancer patients seeking accurate diagnoses to enable their physicians to choose the most effective treatments to improve recovery prospects. Oncology: Onco-hematology Panel This diagnostic test identifies pathogenic variants in 30 genes associated with myelodysplastic syndromes, myeloproliferative neoplasms, and leukemia. It also evaluates over 119 RNA fusions linked to leukemia development. The test simultaneously analyzes DNA for point mutations, small deletions, insertions, and copy number variants (such as SNVs, indels, CNVs), and RNA for chromosomal